Centiva Capital’s KALA BIO KALA Stock Holding History

Centiva Capital’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-23	Closed	-$309K	–	1454
2021 Q2	$309K	Buy	+23	New	+$362K	0.01%	1033

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Centiva Capital's KALA Position: Q3 2021 in Review

Centiva Capital sold out of KALA BIO (KALA) in Q3 2021, closing a stake of 23 shares — an estimated $309K sold.

Centiva Capital first reported a position in KALA in Q2 2021 and held it in 1 quarter. The position peaked at $309K in Q2 2021. 99 funds tracked by Wall St. Rank hold KALA as of Q3 2021.

Centiva Capital reported no remaining KALA BIO position as of Q3 2021 after selling out during the quarter.
Centiva Capital sold 23 KALA BIO shares in Q3 2021, an estimated $309K.
Centiva Capital first reported a position in KALA BIO in Q2 2021 and held it in 1 quarter.
Centiva Capital's KALA BIO position peaked at $309K in Q2 2021.
99 funds tracked by Wall St. Rank held KALA BIO as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.